Research programme: neural stem cell therapies - ReNeuron

Drug Profile

Research programme: neural stem cell therapies - ReNeuron

Alternative Names: CTX cells - ReNeuron; ReN 004; ReN 005

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ReNeuron
  • Class Stem cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Huntington's disease; Neurological disorders; Parkinson's disease

Most Recent Events

  • 28 Nov 2016 StemCells has been acquired by Microbot Medical
  • 15 Aug 2013 No development reported - Preclinical for Huntington's disease, Parkinson's disease and other neurological disorders in United Kingdom (Intracranial)
  • 15 Aug 2013 ReNeuron plans a phase I trial for Peripheral arterial occlusive disorders in United Kingdom (NCT01916369)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top